AU2019239300A1 - Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery - Google Patents

Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery Download PDF

Info

Publication number
AU2019239300A1
AU2019239300A1 AU2019239300A AU2019239300A AU2019239300A1 AU 2019239300 A1 AU2019239300 A1 AU 2019239300A1 AU 2019239300 A AU2019239300 A AU 2019239300A AU 2019239300 A AU2019239300 A AU 2019239300A AU 2019239300 A1 AU2019239300 A1 AU 2019239300A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
eudragit
peptide
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019239300A
Other languages
English (en)
Inventor
John Harold DODD
Stephen Kwaku DORDUNOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of AU2019239300A1 publication Critical patent/AU2019239300A1/en
Priority to AU2025201154A priority Critical patent/AU2025201154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2019239300A 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery Abandoned AU2019239300A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201154A AU2025201154A1 (en) 2018-03-23 2025-02-19 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647000P 2018-03-23 2018-03-23
US62/647,000 2018-03-23
PCT/US2019/023575 WO2019183472A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201154A Division AU2025201154A1 (en) 2018-03-23 2025-02-19 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Publications (1)

Publication Number Publication Date
AU2019239300A1 true AU2019239300A1 (en) 2020-11-19

Family

ID=67988087

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019239300A Abandoned AU2019239300A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
AU2025201154A Pending AU2025201154A1 (en) 2018-03-23 2025-02-19 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201154A Pending AU2025201154A1 (en) 2018-03-23 2025-02-19 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Country Status (13)

Country Link
US (1) US20220088146A1 (https=)
EP (1) EP3768245A4 (https=)
JP (1) JP2021523931A (https=)
KR (1) KR102743821B1 (https=)
CN (1) CN112188888A (https=)
AU (2) AU2019239300A1 (https=)
BR (1) BR112020019128A2 (https=)
CA (1) CA3095036A1 (https=)
EA (1) EA202092275A1 (https=)
IL (1) IL277496B2 (https=)
MX (1) MX2020009900A (https=)
PH (1) PH12020551596A1 (https=)
WO (1) WO2019183472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220137043A (ko) * 2020-02-03 2022-10-11 팔라틴 테크놀로지스 인코포레이티드 디아민-연결 수용체-특이적 고리형 펩티드
JPWO2024143501A1 (https=) * 2022-12-28 2024-07-04

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101726893B1 (ko) * 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
WO2010144341A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
CA2833676C (en) * 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
PL2659881T3 (pl) * 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20150307754A1 (en) * 2014-04-28 2015-10-29 Celanese Acetate Llc Adhesives that include highly-plasticized cellulose esters and methods and articles relating thereto
US10588864B2 (en) * 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery

Also Published As

Publication number Publication date
JP2021523931A (ja) 2021-09-09
BR112020019128A2 (pt) 2021-01-12
EP3768245A1 (en) 2021-01-27
PH12020551596A1 (en) 2021-08-16
IL277496B2 (en) 2025-01-01
IL277496A (en) 2020-11-30
IL277496B1 (en) 2024-09-01
CN112188888A (zh) 2021-01-05
US20220088146A1 (en) 2022-03-24
KR102743821B1 (ko) 2024-12-18
WO2019183472A1 (en) 2019-09-26
MX2020009900A (es) 2021-01-08
KR20210003759A (ko) 2021-01-12
CA3095036A1 (en) 2019-09-26
EP3768245A4 (en) 2023-10-18
AU2025201154A1 (en) 2025-03-13
EA202092275A1 (ru) 2021-02-09

Similar Documents

Publication Publication Date Title
US11286280B2 (en) Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy
US10106578B2 (en) Melanocortin-1 receptor-specific linear peptides
EP2440572B1 (en) Lactam-bridged melanocortin receptor-specific peptides
AU2010259278A1 (en) Melanocortin receptor-specific peptides
AU2025201154A1 (en) Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted